In sum, the analyses provided new insights into molecular mechanisms underlying GBM etiology, identifying GCSF driving tumorgenicity, potential biological and clinical significant markers for therapeutic prognostic and diagnostic implications. The gene discussed is CSF3; the disease is glioblastoma.